Advertisement
ABVC vs KNSA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABVC is a Hold and KNSA is a Hold.
ABVC in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 15, 2026
ABVC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 41 cases where ABVC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ABVC as a result. In 70 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for ABVC just turned positive on October 22, 2026. Looking at past instances where ABVC's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.
ABVC moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ABVC crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +11.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABVC advanced for three days, in 197 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABVC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ABVC entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.824) is normal, around the industry mean (3.151). P/E Ratio (-3.759) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (27.397) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. ABVC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABVC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
KNSA in upward trend: price rose above 50-day moving average on October 27, 2026
KNSA moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 31 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 64 cases where KNSA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on KNSA as a result. In 78 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for KNSA just turned positive on October 27, 2026. Looking at past instances where KNSA's MACD turned positive, the stock continued to rise in 32 of 42 cases over the following month. The odds of a continued upward trend are 76%.
The 10-day moving average for KNSA crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +30.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where KNSA advanced for three days, in 231 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KNSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
KNSA broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KNSA entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 1 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. KNSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.353) is normal, around the industry mean (8.801). P/E Ratio (89.792) is within average values for comparable stocks, (-2.500). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (7.564) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
ABVC | KNSA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 4 | 45 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 41 Fair valued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 1 | |
SMR RATING 1..100 | 98 | 59 | |
PRICE GROWTH RATING 1..100 | 62 | 35 | |
P/E GROWTH RATING 1..100 | 29 | 96 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABVC's Valuation (41) in the null industry is somewhat better than the same rating for KNSA (82) in the Pharmaceuticals Major industry. This means that ABVC’s stock grew somewhat faster than KNSA’s over the last 12 months.
KNSA's Profit vs Risk Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for ABVC (100) in the null industry. This means that KNSA’s stock grew significantly faster than ABVC’s over the last 12 months.
KNSA's SMR Rating (59) in the Pharmaceuticals Major industry is somewhat better than the same rating for ABVC (98) in the null industry. This means that KNSA’s stock grew somewhat faster than ABVC’s over the last 12 months.
KNSA's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as ABVC (62) in the null industry. This means that KNSA’s stock grew similarly to ABVC’s over the last 12 months.
ABVC's P/E Growth Rating (29) in the null industry is significantly better than the same rating for KNSA (96) in the Pharmaceuticals Major industry. This means that ABVC’s stock grew significantly faster than KNSA’s over the last 12 months.
| ABVC | KNSA | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 81% |
| Stochastic ODDS (%) | 1 day ago 86% | 1 day ago 77% |
| Momentum ODDS (%) | 1 day ago 81% | 1 day ago 82% |
| MACD ODDS (%) | 1 day ago 80% | 1 day ago 76% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 80% |
| Advances ODDS (%) | 8 days ago 82% | 1 day ago 76% |
| Declines ODDS (%) | 11 days ago 90% | 4 days ago 74% |
| BollingerBands ODDS (%) | 1 day ago 88% | 1 day ago 80% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 70% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABVC’s FA Score shows that 1 FA rating(s) are green while KNSA’s FA Score has 1 green FA rating(s).
- ABVC’s FA Score: 1 green, 4 red.
- KNSA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABVC’s TA Score shows that 6 TA indicator(s) are bullish while KNSA’s TA Score has 6 bullish TA indicator(s).
- ABVC’s TA Score: 6 bullish, 3 bearish.
- KNSA’s TA Score: 6 bullish, 4 bearish.
Price Growth
ABVC (@Biotechnology) experienced а +9.00% price change this week, while KNSA (@Pharmaceuticals: Generic) price change was +19.42% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +8.21%. For the same industry, the average monthly price growth was -7.17%, and the average quarterly price growth was -10.71%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.77%. For the same industry, the average monthly price growth was -8.99%, and the average quarterly price growth was +6.44%.
Reported Earning Dates
ABVC is expected to report earnings on Oct 30, 2026.
KNSA is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Biotechnology (+8.21% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (+0.77% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement